Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AMGN

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on Tuesday.

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

On Wednesday, Amgen Inc. (NASDAQ:AMGN) and its partner Zai Lab (NASDAQ:ZLAB) said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed.

Is Amgen Stock Underperforming the S&P 500?

Is Amgen Stock Underperforming the S&P 500?

Analysts continue to favor Amgen stock, despite its relative underperformance to the broader S&P 500 Index.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX).

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program

Three major pharmaceutical companies — Amgen Inc. (NASDAQ:AMGN), Eli Lilly and Co (NYSE:LLY), and UCB SA (OTC:UCBJY) (OTC:UCBJF) — are suing U.S. Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. over the way his department is handling a drug discount program.

Amgen Delivers Beat And Raise Quarter; Has Strong Late-Stage Pipeline

Amgen Inc‘s (NASDAQ:AMGN) second quarter results demonstrate ongoing development of its late-stage pipeline “to offset end-of-decade losses-of-exclusivity," according to Goldman Sachs.

inkl

Read news from The Economist, FT, and more,
with one subscription

Do Wall Street Analysts Like Amgen Stock?

Do Wall Street Analysts Like Amgen Stock?

Amgen has notably outpaced the broader market and the healthcare sector in 2025, and analysts remain cautiously optimistic about the stock’s prospects.

Earnings Preview: What to Expect From Amgen’s Report

Earnings Preview: What to Expect From Amgen’s Report

Amgen is set to release its second-quarter earnings next month, and analysts are projecting modest single-digit growth in profit.

Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update

Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update

Amgen Inc (NASDAQ:AMGN) shares are trading lower by 5.7% to $272.88 Monday afternoon after the company released full results from part one of its phase two study of MariTide, its investigational obesity treatment.

How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks?

How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks?

Amgen has underperformed the Pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Amgen Stock Outlook: Is Wall Street Bullish or Bearish?

Amgen Stock Outlook: Is Wall Street Bullish or Bearish?

Although Amgen has lagged behind the broader market over the past year, Wall Street analysts remain cautiously optimistic about the company’s long-term outlook.

Stocks Soar Before the Open on Upbeat Microsoft and Meta Results, More Big Tech Earnings on Tap

Stocks Soar Before the Open on Upbeat Microsoft and Meta Results, More Big Tech Earnings on Tap

June S&P 500 E-Mini futures (ESM25) are up +1.18%, and June Nasdaq 100 E-Mini futures (NQM25) are up +1.68% this morning as forecast-beating quarterly results from Microsoft and Meta boosted sentiment.

Amgen's Quarterly Earnings Preview: What You Need to Know

Amgen's Quarterly Earnings Preview: What You Need to Know

Amgen is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

Get all your
news in one place.

100's of premium titles.
One news app.

Is Bristol-Myers Stock Outperforming the Dow?

As Bristol-Myers has outperformed the Dow recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Amgen Stock: Is AMGN Outperforming the Healthcare Sector?

Amgen has outperformed the healthcare sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

3 Pharmaceutical Stocks Betting Big on Weight Loss Drugs

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

Wall Street Predicts This Dividend Stock to Soar 31%: Should You Buy The Dip Now?

Amgen stock is an attractive buy on the dip for passive income-focused investors.

Get all your
news in one place.

100's of premium titles.
One news app.

3 Biotech Stocks Revolutionizing Healthcare

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and transformative partnerships. To capitalize on this trend, consider adding Amgen (AMGN), BioNTech (BNTX), and Gilead Sciences (GILD), which could boost your portfolio.

Earnings Miss? Amgen’s Dividend Still a Bright Spot

AMGN stock is down over 1% despite beating revenue and earnings estimates; investors are selling the news on the company’s latest obesity drug and weak guidance

Stock Index Futures Slip on Trade War Concerns, U.S. JOLTs Report and Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.11% this morning as investors adopted a cautious stance after China retaliated to new U.S. tariffs.

Stock Index Futures Muted Ahead of U.S. JOLTs Report and Fed Speak, Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.01%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.08% this morning as investors awaited the latest reading on U.S. job openings, comments from Federal Reserve officials, and corporate earnings reports from heavyweight names.

Are Wall Street Analysts Predicting Amgen Stock Will Climb or Sink?

Despite Amgen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

3 Biotech Stocks Revolutionizing Healthcare

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth. Thus, investing in fundamentally stable stocks, Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD), could be a wise way to capitalize on the industry’s growing momentum. Read more….

Amgen’s Q4 2024 Earnings: What to Expect

Drug manufacturing giant Amgen is expected to announce its fourth-quarter results in the upcoming month and analysts expect single-digit growth in earnings.

1 2 3 4 5

People

203,240 stories

Austan Goolsbee

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Corporate Earnings

Places

399,253 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play